Tools
Tools
Ish-Shalom, Sofia, Caraco, Yoseph, Saba Khazen, Nariman, Gershinsky, Michal, Szalat, Auryan, Schwartz, Phillip, Ehud Arbit, Ehud, Galitzer, Hillel, Tang, Jonathan C Y 
ORCID: https://orcid.org/0000-0001-6305-6333, Burshtein, Gregory, Rothner, Ariel, Raskin, Arthur, Blum, Miriam and Fraser, William
(2021)
Safety and efficacy of oral human parathyroid hormone (1-34) in hypoparathyroidism: An open-label study.
Journal of Bone and Mineral Research, 36 (6).
pp. 1060-1068.
ISSN 0884-0431
Preview |
PDF (Accepted_Manuscript)
- Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (367kB) | Preview |
Abstract
The standard treatment of primary hypoparathyroidism (hypoPT) with oral calcium supplementation and calcitriol (or an analog), intended to control hypocalcemia and hyperphosphatemia and avoid hypercalciuria, remains challenging for both patients and clinicians. In 2015, human parathyroid hormone (hPTH) (1-84) administered as a daily subcutaneous injection was approved as an adjunctive treatment in patients who cannot be well controlled on the standard treatments alone. This open-label study aimed to assess the safety and efficacy of an oral hPTH(1-34) formulation as an adjunct to standard treatment in adult subjects with hypoparathyroidism. Oral hPTH(1-34) tablets (0.75 mg human hPTH(1-34) acetate) were administered four times daily for 16 consecutive weeks, and changes in calcium supplementation and alfacalcidol use, albumin-adjusted serum calcium (ACa), serum phosphate, urinary calcium excretion, and quality of life throughout the study were monitored. Of the 19 enrolled subjects, 15 completed the trial per protocol. A median 42% reduction from baseline in exogenous calcium dose was recorded (p =.001), whereas median serum ACa levels remained above the lower target ACa levels for hypoPT patients (>7.5 mg/dL) throughout the study. Median serum phosphate levels rapidly decreased (23%, p =.0003) 2 hours after the first dose and were maintained within the normal range for the duration of the study. A notable, but not statistically significant, median decrease (21%, p =.07) in 24-hour urine calcium excretion was observed between the first and last treatment days. Only four possible drug-related, non-serious adverse events were reported over the 16-week study, all by the same patient. A small but statistically significant increase from baseline quality of life (5%, p =.03) was reported by the end of the treatment period. Oral hPTH(1-34) treatment was generally safe and well tolerated and allowed for a reduction in exogenous calcium supplementation, while maintaining normocalcemia in adult patients with hypoparathyroidism.
| Item Type: | Article |
|---|---|
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Musculoskeletal Medicine Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 13 Feb 2021 01:04 |
| Last Modified: | 19 Oct 2023 02:54 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/79243 |
| DOI: | 10.1002/jbmr.4274 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |